-
公开(公告)号：US20230233615A1
公开(公告)日：2023-07-27
申请号：US18097509
申请日：2023-01-17
Inventor： Chi-Ying Huang , Yu-Chen Tsai , Ming-Hsi Chuang , Po-Cheng Lin
IPC: A61K35/28 , A61P25/28 , C12N15/113 , C12N9/64 , C12N5/0775
CPC classification number: A61K35/28 , A61P25/28 , C12N5/0667 , C12N9/6494 , C12N15/113 , C12Y304/24011 , C12N2310/141 , C12N2310/531 , C12N2500/32 , C12N2500/42
Abstract: The present disclosure provides a pharmaceutical composition for treating Alzheimer’s disease, which at least includes an extracellular vesicle that is prepared by a method including: a first culturing step: performing an amplification culture of an adipose-derived stem cell in a first culture medium at a cell density of 6,000-15,000 cells/cm2 until an amplification amount of the adipose-derived stem cell is above 90% of that before the culture; a second culturing step: culturing the amplified adipose-derived stem cell in a second culture medium at a cell density of 10,000-100,000 cells/cm2 for 20-30 hours; and an extracellular vesicle separating step: collecting a culture solution and separating the extracellular vesicle from the culture solution by utilizing a tangential flow filtration (TFF) or ultrafiltration method.
-
Patent Agency Ranking
公开(公告)号：US20240117314A1
公开(公告)日：2024-04-11
申请号：US18376440
申请日：2023-10-03
Inventor： Ruei-Yue Liang , Chia-Hsin Lee , Kai-Ling Zhang , Po-Cheng Lin , Ming-Hsi Chuang , Yu-Chen Tsai , Peggy Leh Jiunn Wong
IPC: C12N5/0775 , A01N1/02 , A61K35/28 , A61P3/10
CPC classification number: C12N5/0662 , A01N1/0284 , A61K35/28 , A61P3/10 , C12N2500/32 , C12N2500/38
Abstract: The present invention relates to a method for preparing a modified stem cell, including the following steps: a cell culture step: culturing stem cells in a first culture medium of a culture dish at a predetermined cell density, and removing the first culture medium after a first culture time to obtain a first cell intermediate; an activity stimulation step: preserving the first cell intermediate in a freezing container having a cell cryopreservation solution, and performing a constant temperature stimulation treatment or a variable temperature stimulation treatment for at least more than 1 day; and a product collection step: after completing the activity stimulation step, placing the freezing container in an environment at a thawing temperature for thawing, and then removing the cell cryopreservation solution to obtain the modified stem cell. The modified stem cell can release at least one or more of IL-4, IL-5, IL-13, G-CSF, Fractalkine, and EGF.
-
公开(公告)号：US20250136661A1
公开(公告)日：2025-05-01
申请号：US18525926
申请日：2023-12-01
Applicant: GWO XI STEM CELL APPLIED TECHNOLOGY CO., LTD
Inventor： Hsiu-Jung Liao , Ssu-Jung Lu , Yu-Chen Tsai , Po-Cheng Lin , Ming-Hsi Chuang
IPC: C07K14/705 , A61K9/00 , A61K35/28 , A61P19/02 , A61P29/00
Abstract: The present disclosure provides a pharmaceutical composition including an adipose tissue-derived extracellular vesicle and a biologic, and a use of the pharmaceutical composition for treating arthritis. The pharmaceutical composition of the present disclosure achieves the effect of treating arthritis through various efficacy experiments.
-
公开(公告)号：US20250144150A1
公开(公告)日：2025-05-08
申请号：US19012977
申请日：2025-01-08
Inventor： Po-Cheng Lin , Pi-Chun Huang , Chia-Hsin Lee , Ming-Hsi Chuang , Chun-Hung Chen , Chao-Liang Chang , Kai-Ling Zhang , Yi-Chun Lin , Yu-Chen Tsai , Peggy Leh Jiunn Wong , Ruei-Yue Liang
IPC: A61K35/28 , A61K9/00 , A61K38/18 , A61K38/19 , A61K38/20 , A61K45/06 , A61P25/28 , C12N5/00 , C12N5/0775
Abstract: The present invention provides a preparation method of pharmaceutical composition for treating chronic stroke, involving injection via brain into the cranium of a patient having chronic stroke for six months or more; the pharmaceutical composition is a suspension at least comprising adipose-derived stem cells treated by cell expansion, an active synergistic component and a growth factor, wherein the expression level of CD34 and CD45 of the adipose-derived stem cells treated by cell expansion is 10% or less, and the expression level of CD90 and CD105 is 90% or more; the active synergistic component is an extracellular vesicle; the growth factor is at least one selected from the group consisting of HGF, G-CSF, Fractalkine, IP-10, EGF, IL-1α, IL-1β, IL-4, IL-5, IL-13, IFNγ, TGFα and sCD40L. The present invention overcomes the limitations of previous cell therapy and provides a cell-based preparation that is clinically safe and therapeutically effective for chronic cerebral stroke.
-
公开(公告)号：US20240117316A1
公开(公告)日：2024-04-11
申请号：US18376566
申请日：2023-10-04
Inventor： Yu-Chen Tsai , Ming-Hsi Chuang , Po-Cheng Lin
IPC: C12N5/0775 , A61K35/28
CPC classification number: C12N5/0665 , A61K35/28
Abstract: The present disclosure provides a method for preparing mesenchymal stem cell-derived extracellular vesicle, the mesenchymal stem cell-derived extracellular vesicle prepared by the method, and use of the mesenchymal stem cell-derived extracellular vesicle for reducing adipogenesis and treating osteoarthritis. The mesenchymal stem cell-derived extracellular vesicle of the present disclosure achieves the effect of reducing adipogenesis and treating osteoarthritis through various efficacy experiments.
-
公开(公告)号：US20230233613A1
公开(公告)日：2023-07-27
申请号：US17963219
申请日：2022-10-11
Inventor： Po-Cheng Lin , Pi-Chun Huang , Chia-Hsin Lee , Ming-Hsi Chuang , Chun-Hung Chen , Chao-Liang Chang , Kai-Ling Zhang , Yi-Chun Lin , Yu-Chen Tsai , Peggy Leh Jiunn Wong , Ruei-Yue Liang
IPC: A61K35/28 , A61K9/00 , C12N5/0789
CPC classification number: A61K35/28 , A61K9/0085 , A61K9/0019 , C12N5/0647 , C12N2501/10 , C12N2502/1382 , C12N2501/2304 , C12N2501/2313
Abstract: The present invention provides a pharmaceutical composition for treating chronic stroke, involving injection via brain into the cranium of a patient having chronic stroke for six months or more; the pharmaceutical composition is a suspension at least comprising TS stem cells, an active synergistic component and a growth factor, wherein the expression level of CD34 and CD45 of the TS stem cells is 10% or less, and the expression level of CD90 and CD105 is 90% or more; the active synergistic component is an extracellular vesicle; the growth factor is at least one selected from the group consisting of HGF, G-CSF, Fractalkine, IP-10, EGF, IL-1α, IL-1β, IL-4, IL-5, IL-13, IFNγ, TGFα and sCD40L. The present invention overcomes the limitations of previous cell therapy and provides a cell-based preparation that is clinically safe and therapeutically effective for chronic cerebral stroke.
-
-
-
-
-
Search Results
6
records
(took 0.014 seconds)
